Roche offers an upbeat two-plus-year look at its anti-TIGIT combo therapy — but will two deaths hurt its chances?
Roche’s Genentech got a leg up in the packed anti-TIGIT race earlier this year when the FDA granted it the first breakthrough designation in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
